How finally accepting her diagnosis and being proactive with her health helped one woman manage her lung condition.

An Insmed drug developed for a serious chronic lung disorder with no FDA-approved therapies handily beat a placebo in a pivotal clinical trial, preliminary results that set the stage for a regulatory ...

Insmed's freshly approved lung condition drug soared past sales expectations for 2025, netting $144.6 million in its first ...

The bronchiectasis market is expected to experience steady growth, with a strong CAGR projected from 2024 to 2034. This growth in the 7MM will be fueled by the launch of new treatments like ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Bronchiectasis ...

New York, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Bronchiectasis Drugs in Development by Stages, Target, MoA, RoA ...

Dr Metersky provides his closing thoughts, highlighting key points of emphasis surrounding bronchiectasis care and the future of its treatment landscape. Pamela J. McShane, MD, explores the clinical ...

Bronchiectasis is a chronic condition of the respiratory system, in which there is abnormal widening of the airways due to an initial damaging factor. This in turn reduces the ability of the bronchi ...

Study met its primary endpoint demonstrating safety and tolerability of CMTX-101 in people with cystic fibrosisCMTX-101 ...

A pulmonary specialist shares his approach to treating patients with bronchiectasis, highlighting gaps in knowledge that impact management practices. What are the current gaps in knowledge regarding ...

Suspected bronchiectasis, defined as a combination of clinical symptoms and radiologic evidence of abnormal airways, is associated with a 15% higher risk for death in adults with normal spirometry, ...